Summary from the GEO: "Hepatocellular carcinoma (HCC) has dismal treatment responses to systemic therapies and is caused by both, viral and non-viral etiologies, including non-alcoholic steatohepatitis (NASH) 1–5. NASH - triggered by high caloric intake and sedentary lifestyle - has become an important driver for HCC development. Immunotherapy has been recently approved for HCC but stratification...

Investigating the NASH-triggered HCC in the context PD-1-targeted immunotherapy with flow cytometry, single cell RNA sequencing, immunohistochemistry and mass spectrometric analyses, we found a progressive increase of CD8+PD-1+ effector T-cells with a unique profile of exhaustion and activation markers rising with murine and human NASH severity. Notably, late-stage HCC treatment with PD-1-targeted...

Summary from the GEO: "Whereas some cancer types (e.g. melanoma) can be efficiently treated with immunotherapy, others lack measurable positive effects (e.g. PDAC ). Moreover, stratification of responders/non-responders is only possible in some cancer types (e.g. melanoma). Hepatocellular carcinoma (HCC) has a dismal prognosis, limited treatment options and survival benefit, and represents a potential...

Summary from the ENA: "Mice with advanced non alcoholic fatty liver disease (NASH) by dietary feeding regime of choline deficient high fat diet (CD-HFD) were treated with antibodies (a-CD8 depletion; a-PD1 checkpoint inhibition; Co-depletion by a-CD8 and a-NK1.1 administration) for 8 weeks. Surprisingly, a-CD8 depletion prevented hepatocarcinogenesis; in contrast a-PD1 checkpoint inhibition induced...